Trials / Completed
CompletedNCT04979884
Safety and Effectiveness of Cyclosporin in the Management of COVID19 ARDS Patients in Alexandria University Hospital
Safety and Therapeutic Efficacy of Cyclosporine Plus Standard of Care Treatment on ARDS in COVID -19 Patients at Alexandria University Hospitals in 2021: a Comparative Study
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 66 (actual)
- Sponsor
- Alexandria University · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The study to evaluate the effect of cyclosporine ( IL2 inhibitor and antiviral) verse standard care treatment on decrease ADRS, hyper inflammation, hypercytokinemia, and the mortality rate
Detailed description
To test the efficacy of IL-2 inhibitors (Cyclosporine) compared to the Standard of care according to hospital protocol on COVID-19 patients concerning the clinical outcome (cytokines level, clinical improvement, and PCR of SARS-CoV-2 through the study period). AIM: The slow progression of the disease, improving survival among COVID-19 patients, and Standard assessment of patient improvement. * Standard assessment of patient improvement: * PCR-SARS-CoV-2 negative * No fever * No cytopenia (Hb ≥90 g/L, ANC ≥0.5x109/L, platelets ≥100x109/L) • * No hyperferritinemia ≥500 μg/L * (Decrease of IL2)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | cyclosporine | Dose of Cyclosporine oral capsule of 6 mg/kg/day divided into two doses with normal kidney function for 8-14 days |
Timeline
- Start date
- 2022-01-03
- Primary completion
- 2022-09-09
- Completion
- 2022-12-09
- First posted
- 2021-07-28
- Last updated
- 2025-05-14
Locations
1 site across 1 country: Egypt
Source: ClinicalTrials.gov record NCT04979884. Inclusion in this directory is not an endorsement.